Nolvadex Falls To Generic Competition: AstraZeneca To Discontinue Tamoxifen
This article was originally published in The Pink Sheet Daily
AstraZeneca will pull its breast cancer therapy Nolvadex at the end of June.
You may also be interested in...
Trial shows Lilly’s Evista reduces risk of developing invasive breast cancer by 50%, comparable to AstraZeneca’s Nolvadex.
The Government Accountability Office recommends that Congress establish a bundled payment system for end-stage renal disease services - including Amgen's Epogen (epoetin) - under Medicare Part B "as soon as possible.